141 related articles for article (PubMed ID: 23390452)
21. Eyelash trichomegaly induced by erlotinib for metastatic lung cancer.
Chan JYY; Kwok TYT; Yuen HKL
Hong Kong Med J; 2021 Feb; 27(1):60.e1-60.e3. PubMed ID: 33568562
[No Abstract] [Full Text] [Related]
22. A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva).
Márquez G; Herrera-Acosta E; Vidal I; Galvany L; Iglesias M; Umbert P
Int J Dermatol; 2009 Jan; 48(1):97-8. PubMed ID: 19126063
[No Abstract] [Full Text] [Related]
23. Eyelash length for the diagnosis of atopic dermatitis and ichthyosis vulgaris in children-a case control study.
Singh M; Pawar M
Eur J Pediatr; 2018 Jun; 177(6):955-960. PubMed ID: 29675643
[TBL] [Abstract][Full Text] [Related]
24. Acquired trichomegaly: trichomegaly secondary to erlotinib.
Medina Mendez CA; Ma PC; Singh AD
JAMA Ophthalmol; 2014 Sep; 132(9):1051. PubMed ID: 25078467
[No Abstract] [Full Text] [Related]
25. Triad of trichomegaly, alopecia and male-pattern hair growth during treatment with erlotinib in non-small-cell lung cancer.
Forde P; Murphy C; O'Sullivan C; Carney D
Ir J Med Sci; 2011 Mar; 180(1):283-4. PubMed ID: 20108129
[TBL] [Abstract][Full Text] [Related]
26. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
27. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
28. Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression.
Gabr AG; Goto H; Hanibuchi M; Ogawa H; Kuramoto T; Suzuki M; Saijo A; Kakiuchi S; Trung VT; Sakaguchi S; Moriya Y; Sone S; Nishioka Y
Clin Exp Metastasis; 2012 Mar; 29(3):207-16. PubMed ID: 22170031
[TBL] [Abstract][Full Text] [Related]
29. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
De Pas T; Toffalorio F; Manzotti M; Fumagalli C; Spitaleri G; Catania C; Delmonte A; Giovannini M; Spaggiari L; de Braud F; Barberis M
J Thorac Oncol; 2011 Nov; 6(11):1895-901. PubMed ID: 21841502
[TBL] [Abstract][Full Text] [Related]
30. Trichomegaly Induced by Cetuximab: Case Series and Review the Literature.
Koksal UI; Pilanci KN; Ordu C; Okutur K; Saglam S; Demir G
Am J Ther; 2016; 23(5):e1226-9. PubMed ID: 26079631
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
Johnson ML; Riely GJ; Rizvi NA; Azzoli CG; Kris MG; Sima CS; Ginsberg MS; Pao W; Miller VA
J Thorac Oncol; 2011 Jun; 6(6):1128-31. PubMed ID: 21623279
[TBL] [Abstract][Full Text] [Related]
32. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
[TBL] [Abstract][Full Text] [Related]
33. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
34. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib.
Braiteh F; Kurzrock R; Johnson FM
J Clin Oncol; 2008 Jul; 26(20):3460-2. PubMed ID: 18612164
[No Abstract] [Full Text] [Related]
35. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
36. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
37. Scanning electron microscopy of panitumumab-induced eyelash and hair alterations - Pili canaliculi.
Sarzi Sartori D; Larangeira de Almeida A; Santana Pereira de Oliveira G; de Almeida HL
An Bras Dermatol; 2022; 97(2):240-242. PubMed ID: 35042642
[TBL] [Abstract][Full Text] [Related]
38. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
Cho SH; Park LC; Ji JH; Park S; Hwang DW; Lee JY; Choi YL; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
Cancer Chemother Pharmacol; 2012 Aug; 70(2):315-20. PubMed ID: 22760226
[TBL] [Abstract][Full Text] [Related]
40. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
